UVA1 phototherapy for cutaneous diseases: An experience of 92 cases in the United States

76Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The efficacy and safety of UVA1 (340-400nm) phototherapy were established by studies from European countries. Purpose: Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States. Methods: A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed. Results: Two-third of the patients showed a fair to good response (26-100% improvement) and one-third of the patients showed a poor response (0-25% improvement). Diseases with a moderate to good response (51-100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I-III responded better that those with a darker skin type. Conclusion: UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions. © 2006 Blackwell Munksgaard.

Author supplied keywords

Cite

CITATION STYLE

APA

Tuchinda, C., Kerr, H. A., Taylor, C. R., Jacobe, H., Bergamo, B. M., Elmets, C., … Lim, H. W. (2006). UVA1 phototherapy for cutaneous diseases: An experience of 92 cases in the United States. Photodermatology Photoimmunology and Photomedicine, 22(5), 247–253. https://doi.org/10.1111/j.1600-0781.2006.00245.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free